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sitivity analysis (PSA) was run with thousand repetitions and a one-way sensitiv-
ity analysis was calculated showing its results in a tornado chart. Results: The 
model showed that everolimus + exemestane results in 0.74 progression free years 
gained with an incremental cost of $18.6 million (MM) resulting in an incremental 
cost-effectiveness ratio (ICER) of $26 MM. The PSA showed that the ICER is within 
the range recommended by WHO (1-3 GDPs per capita) in 71% of cases (Currently 
the GDP per capita in Chile is $10 MM). ConClusions: This analysis showed 
that using everolimus plus exemestane in patients with ER +, HER2- advanced 
breast cancer who have failed on NSAIs is a cost-effective option according to 
WHO recommendations.
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objeCtives: Slovakia is a country with high incidence and mortality of cervical 
cancer (CC). Despite the improvements in screening (22.9% coverage rate), the CC 
incidence has increased over the past 30 years in Slovakia. Human Papillomavirus 
(HPV) vaccination could help to reduce this CC burden. The objective of this analy-
sis was to assess the cost-effectiveness of adding the AS04-adjuvanted HPV-16/18 
vaccine (AS04V), using a 2-dose administration schedule, to the current CC screen-
ing programme in Slovakia. Methods: A previously published Markov cohort 
model, reproducing the natural history of HPV infection, the impact of screening 
and vaccination, was adapted to the Slovakian settings. Local data on health care 
costs of pre-cancer lesions and CC, obtained from the expert panel, were used. 
Transition probabilities and utilities were estimated from published data. Costs 
were from a health care payer perspective. The incremental CC cases avoided, cost, 
quality-adjusted life-years (QALYs) and resulting cost-effectiveness ratio (ICER) 
of AS04V added to the current CC screening programme versus the current CC 
screening in Slovakia was estimated. The base case assumes a 100% vaccination 
coverage among 12-year-old girls (N= 24,859). A discount rate of 5% was used. 
Univariate sensitivity analyses were carried out on key parameters. Results: 
Compared to screening alone, adding AS04V to the current screening programme 
was estimated to reduce the lifetime CC cases by 328 at an ICER of 11,621 € /
QALY gained. Compared to the official cut-off of 19,320€ /QALY gained, it can be 
considered as cost-effective. Undiscounted analysis shows that AS04V generates 
more QALYs with similar cost versus screening alone (ICER= 5€ /QALY gained). 
Parameters most driving the results were discount rate, vaccine efficacy and dura-
tion of protection. ConClusions: AS04V vaccination of 12-year-old girls in a 
2-dose schedule was estimated to be a cost-effective CC prevention strategy in 
Slovakia.
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objeCtives: To evaluate the cost-effectiveness of everolimus plus exemestane 
(EVE+EXE) versus chemotherapy agents [docetaxel (DOC), vinorelbine (VIN), dox-
orubicin (DOX) and capecitabine (CAPE)] for the treatment of hormone receptor 
positive (HR+) HER2 negative (HER2-) advanced or metastatic breast cancer in the 
United Kingdom (UK). Methods: A partitioned survival model was developed to 
compare treatment with EVE+EXE versus DOC, VIN, DOX and CAPE in patients with 
ER+ HER2- metastatic breast cancer over a 10-year time horizon from a UK NHS 
perspective. Progression-free survival and overall survival for EVE+EXE were taken 
from the BOLERO-2 trial. Log-logistic functions were used to extrapolate trial data 
beyond the follow-up period. In the absence of head-to-head evidence comparing 
EVE+EXE versus chemotherapy a naïve chained comparison was conducted with 
the link between EVE+EXE established via tamoxifen using the Bucher method. 
A class effect was assumed for the four chemotherapy agents. Background health 
state and terminal care resource use were derived from NICE Clinical Guideline 81. 
Drug costs were taken from the British National Formulary. Utilities for stable and 
progressive states were obtained from the literature (Lloyd et al. 2006). Results: 
Over a ten year time horizon, EVE+EXE led to a life expectancy of 3.55 years, com-
pared to 1.88 for chemotherapy agents (DOC, VIN, DOX and CAPE). EVE+EXE resulted 
in 2.06 QALYs, compared to 0.95 for chemotherapy agents. Total costs were £48,085 
for EVE+EXE compared to £31,835 vs. DOC, £25,021 vs. VIN, £23,743 vs. DOX and 
£21,851 vs. CAPE. The incremental costs per QALY were £14,550 vs. DOC, £20,653 vs. 
VIN, £21,797 vs. DOX and £23,491 vs. CAPE. Results were most sensitive to changes 
in PFS for chemotherapy and disease related costs. ConClusions: Everolimus in 
combination with exemestane is a cost effective option compared with commonly 
used chemotherapeutic agents (docetaxel, vinorelbine, doxorubicin and capecit-
abine) in UK clinical practice.
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objeCtives: Bevacizumab in combination with carboplatin/paclitaxel (BCP) was 
approved to be the first-line therapy of advanced NSCLC due to its high clini-
cal efficacy. However, economic effectiveness of BCP has been controversial. This 
study aimed to estimate the cost-effectiveness of BCP versus PC in treatment of 
advanced NSCLC patients from patients’ perspective in Vietnam. Methods: A 
modegib therapy than with SOC for both, laBCC and mBCC patients. ConClusions: 
Vismodegib could provide an effective treatment for this therapeutic area with high 
rate of unmet need. During the adaptation process Delphi-panel surveys seemed 
to be an appropriate method to earn consensus statement to ensure estimation 
and help interpretation.
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objeCtives: The United Kingdom (UK) runs a successful human papillomavirus 
(HPV) girls vaccination programme. Debate is ongoing on the value of including 
boys in the programme. This study aims at quantifying the potential value associ-
ated with genital warts (GW) and HPV-related cancer prevention in UK males and 
females based on a willingness-to-pay threshold of £20,000 per quality-adjusted 
life-years (QALY) gained, representing the potential value a government places 
on the prevention of these diseases. Methods: A static vaccine steady-state 
(VSS) population model, stratified by age, with a 1-year time horizon, replicated 
the incidence of GW and HPV-related cancers in females (cervical (CC), anal (AC), 
vulvar (VuC), vaginal (VaC), oropharyngeal (OP)) and males (penile (PC), AC and 
OP) pre-vaccination and at VSS. Data were retrieved from UK cancer registries, 
sexually transmitted diseases reports and HPVCentre. Costs and utilities were 
identified from the literature. The VSS vaccine effectiveness for GW and HPV-
related cancers was estimated combining efficacies (AS04-adjuvanted HPV-16/18 
vaccine for cancers; HPV-6/11/16/18 vaccine for GW) weighted by vaccine-types 
(HPV-6/11/16/18) and non-vaccine types (HPV-31/33/35/39/45/51/52/56/58/59) HPV 
distribution. Costs and QALYs were discounted at 1.5%. Per-course vaccine cost-
effective price (vCE-p) was determined by increasing vaccine course price until 
£20,000 per incremental QALY gained at VSS was reached. Sensitivity analyses 
on key variables were performed. Results: The vCE-p in women (men) was: CC 
£790, OP £20 (£57), AC £123 (£77), VaC £37, VuC £58, (PC £40), GW £26 (£27). Total 
value of cancer prevention in women (men) was £1,027 (£173), a proportion of 6: 
1. The value of CC alone is 4.5 times larger than the total value of cancer preven-
tion in men. Sensitivity analyses showed results were robust while influenced by 
potential herd protection. ConClusions: The vCE-p was estimated to be up to 
6 times higher in women than in men due to the higher burden and frequency of 
HPV-related cancers in women.
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objeCtives: to evaluate the cost-effectiveness of aprepitant as add-on ther-
apy to the standard Egyptian regimen in patients receiving highly emetogenic 
therapy. Methods: A decision tree model was developed based on the Egyptian 
clinical practice, and was derived from published sources. This decision analyti-
cal model was constructed to assess the costs and consequences associated with 
aprepitant containing regimen compared with standard therapy for Chemotherapy-
Induced Nausea and Vomiting. The clinical parameters were derived from a ran-
domized trial previously published. The utility of the health states was derived 
using the available published data. Direct medical costs were obtained from the 
third party payer tariff in Egypt. Deterministic sensitivity analyses were conducted. 
All costs (in 2014 EGP) and outcomes were discounted at 3.5% annually. Results: 
The total quality-adjusted life-years (QALYs) of adding aprepitant to the standard 
regimen was estimated to be 0.0082, whereas that of the standard regimen was 
estimated to be 0.0072 (with a net difference of 0.001QALYs). The total costs for 
aprepitant plus standard regimen and standard regimen alone were EGP 414.25 
and EGP 346.62 respectively (with a net difference of EGP 67.63). Thus the incre-
mental cost-effectiveness ratio (ICER) for aprepitant was EGP 66,004/QALY gained. 
The probability of complete protection and incomplete response of both arms 
were found to have the greatest effect on the results. ConClusions:  The present 
study concludes that adding aprepitant to the standard regimen is cost effective 
based on the threshold stated by world health organization (3xGDP/capita) for 
patients with severe vomiting after chemotherapy.
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objeCtives: To evaluate the cost-effectiveness of everolimus plus exemes-
tane in patients with ER+, HER2- advanced breast cancer, who have failed on 
NSAIs. Methods: A Markov model was developed with monthly cycles and a 
time horizon of five years. The model compares progression free survival (PFS) of 
exemestane + everolimus (EVE+EXE) to exemestane monotherapy (EXE). Transition 
probabilities for PFS of EVE+EXE and EXE were based on BOLERO-2 study and calcu-
lated using a fitted Weibull distribution. The R-squared values for the Weibull fits 
were 0.998 and 0.990 for EVE+EXE and EXE alone respectively. The Weibull param-
eters used in the model were: 0.067 and 1.118 for EVE+EXE and 0.191 and 1.006 for 
EXE. Costs considered included drugs and cost of treating neutropenia (other AEs 
are not covered by the National Formulary). The analysis was designed from the 
perspective of the Chilean Public Healthcare. Results are shown in 2014 Chilean 
pesos. A 5% discount rate for costs and efficacies was applied. A probabilistic sen-
